IDT Biologika Introduces Plans to Expand Vaccine Capacity and Announces Workforce Expansion

IDT Biologika GmbH has introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilization capacity.

IDT Biologika GmbH, a global integrated contract manufacturer of vaccines and biopharmaceuticals, has introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilization capacity. The company also announced the addition of 80 employees to its workforce — an increase of approximately 11 % — to meet growth in demand for its biologics production. IDT Biologika will showcase its integrated production capabilities, from concept through commercialization, at the International Contract Services Exhibition 2010 (ICSE 2010) in Paris (France), being held 5–7 October 2010.

ICSE 2010 will take place at the Villepinte Paris Nord Convention Centre, in conjunction with the CPHI Worldwide. IDT Biologika representatives — including Sonja Stoyantschova, newly hired Director of Sales & Marketing for Pharmaceuticals — will be available to discuss the company’s full suite of manufa